
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/">
  <dc:rights>http://creativecommons.org/licenses/by-nc/3.0/at/legalcode</dc:rights>
  <dc:language>srp</dc:language>
  <dc:contributor id="https://plus.cobiss.net/cobiss/sr/sr/conor/25498983">Jukić, Marin, 1986-</dc:contributor>
  <dc:contributor id="https://plus.cobiss.net/cobiss/sr/sr/conor/12669031">Pešić, Vesna, 1964-</dc:contributor>
  <dc:contributor id="https://plus.cobiss.net/cobiss/sr/sr/conor/22159719">Stanić, Dušanka, 1983-</dc:contributor>
  <dc:contributor id="https://plus.cobiss.net/cobiss/sr/sr/conor/22571367">Miljević, Čedo, 1966-</dc:contributor>
  <dc:contributor id="https://plus.cobiss.net/cobiss/sr/sr/conor/15203175">Starčević, Ana, 1979-</dc:contributor>
  <dc:contributor id="https://plus.cobiss.net/cobiss/sr/sr/conor/54563593">Pavlović, Zorana, 1974-</dc:contributor>
  <dc:creator id="https://plus.cobiss.net/cobiss/sr/sr/conor/28074855">Milosavljević, Filip, 1993-</dc:creator>
  <dc:title xml:lang="srp">Meta-analiza podataka o razlikama u izloženosti psihijatrijskim lekovima između sporih i normalnih CYP2C19/CYP2D6 metabolizera : doktorska disertacija</dc:title>
  <dc:date>2022</dc:date>
  <dc:description xml:lang="srp">Postoji mogućnost da genetski predodređene razlike između osoba u kapacitetu CYP450enzima mogu uticati na farmakoterapiju u psihijatriji. Cilj ovog istraživanja bio je preciznakvantifikacije uticaja CYP2C19/CYP2D6 fenotipa na izloženost antidepresivima iantipsihoticima metodom meta-analize odnosa srednjih vrednosti. Drugi cilj bio jeispitivanje uticaja CYP2C19 fenotipa na efikasnost i podnošljivost antidepresiva pomoćukliničke studije u kojoj su hospitalizovani pacijenti praćeni četiri nedelje.Serija meta-analiza podataka iz 94 jedinstvene studije na ukupno 8379 precizno jekvantifikovala povećanu izloženost escitalopramu (+163%; 95%CI: +140%, 189%;n=1262, p&lt;0,0001) i sertralinu (+38%; 95%CI: +27%, +51%; n=917, p&lt;0,0001) kod osobasa genetski predviđenim smanjenim kapacitetom CYP2C19 enzima, kao i povećanuizloženost risperidonu (+36%; 95%CI: +28%, +44%; n=1492, p&lt;0,0001), aripiprazolu(+48%; 95%CI: +41%, +57%; n=1038, p&lt;0,0001) i haloperidolu (+68%; CI95%: 40%,102%; n=423, p&lt;0.0001) kod osoba sa genetski predviđenim smanjenim kapacitetomCYP2D6 enzima. Klinička studija demonstrirala je da su, u toku četiri nedelje, osobe sasporijim CYP2C19 metabolizmom imale 36% (95%CI: 20-52%, p&lt;0,0001) manje izraženopoboljšanje simptoma depresije (praćeno Hamilton skalom za depresiju) i značajno većiintenzitet neželjenih efekata vezanih za gastrointestinalni (q=0,002) i centralni nervnisistem (q=0,045) što je mereno Toronto skalom, u odnosu na kontrolne osobe.Zbog visoke preciznosti kvantifikacije, rezultati meta-analiza mogu poslužiti kao osnova zakliničke smernice za precizno doziranje ispitivanih lekova na osnovu CYP2C19/CYP2D6genotipa. Takođe, rezultati kliničke studije naglašavaju da CYP2C19 genotip može bitiklinički važna informacija u psihijatrijskoj praksi.</dc:description>
  <dc:description xml:lang="eng">Genetically predicted interindividual differences in activites of CYP450 enzymes maysignificantly influence pharmacotherapy in psychiatry. The aim of this research was toprecisely quantify the influence of CYP2C19/CYP2D6 phenotype on the exposure toantidepressants and antipsychotics with ratio-of-means meta-analysis. Other aim was todetermine the influence of CYP2C19 phenotype on the efficacy and tolerability ofantidepressants in the clinical study of inpatients that were monitored for four weeks.Meta-analyses of the data from 94 unique studies and 8379 participants preciselyquantified the increased exposure to escitalopram (+163%; 95%CI: +140%, 189%;n=1262, p&lt;0.0001) and sertraline (+38%; 95%CI: +27%, +51%; n=917, p&lt;0.0001) inparticipants with genetically predicted decreased CYP2C19 capacity; and increasedexposure to risperidon (+36%; 95%CI: +28%, +44%; n=1492, p&lt;0.0001), aripiprazole(+48%; 95%CI: +41%, +57%; n=1038, p&lt;0.0001) and haloperidol (+68%; CI95%: 40%,102%; n=423, p&lt;0.0001) in participants with genetically predicted decreased CYP2D6enzyme capacity. Clinical study revealed that, during 4 weeks, patients with decreasedCYP2C19 activity had 36% (95%CI: 20-52%, p&lt;0.0001) less pronounced depressionsymptom improvement (monitored with Hamilton depression rating scale), and significantlyhigher intensity of central nervous system (q=0.002) and gastrointestinal (q=0.042)adverse reactions (monitored with Toronto adverse reaction scale), compared to controls.Due to high quantification precision, results of the meta-analyses may serve as a basis forprecise dosing guidelines, for examined drugs, that are based on CYP2C19/CYP2D6genotype. Also, clinical study results suggest that CYP2C19 genotype may be usefulclinical information in psychiatric practice.</dc:description>
  <dc:description xml:lang="srp">Farmaceutske nauke - (Farmakologija) / Pharmacy - (Pharmacology)  Datum odbrane: 21.10.2022. </dc:description>
  <dc:format>81 str.</dc:format>
  <dc:format>8705790 bytes</dc:format>
  <dc:identifier>https://phaidrabg.bg.ac.rs/o:29312</dc:identifier>
  <dc:identifier>cobiss:80769289</dc:identifier>
  <dc:identifier>thesis:9082</dc:identifier>
  <dc:subject xml:lang="eng">OSNO - Opšta sistematizacija naučnih oblasti, Farmacija</dc:subject>
  <dc:subject xml:lang="srp">OSNO - Opšta sistematizacija naučnih oblasti, Farmacija</dc:subject>
  <dc:subject xml:lang="srp">Antidepresivi, Antipsihotici, CYP2C19, CYP2D6, Farmakogenetika, Precizna medicina, Meta-analiza, Klinička studija</dc:subject>
  <dc:subject xml:lang="eng">Antidepressants, Antipsychotics, CYP2C19, CYP2D6, Pharmacogenetics, Precise medicine, Meta-analysis, Clinical study</dc:subject>
  <dc:subject xml:lang="srp">615.214:577.2(043.3) </dc:subject>
  <dc:type>info:eu-repo/semantics/bachelorThesis</dc:type>
</oai_dc:dc>
